FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of FibroGen stock in a transaction that occurred on Thursday, June 21st. The stock was sold at an average price of $63.62, for a total transaction of $2,521,642.32. Following the sale, the chief executive officer now owns 2,856,353 shares in the company, valued at $181,721,177.86. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NASDAQ FGEN traded up $0.55 during midday trading on Friday, reaching $64.95. The stock had a trading volume of 1,424,561 shares, compared to its average volume of 544,648. The company has a market capitalization of $5.34 billion, a P/E ratio of -37.54 and a beta of 1.95. FibroGen Inc has a twelve month low of $30.95 and a twelve month high of $65.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 8.61 and a current ratio of 8.61.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.51) by $0.01. The firm had revenue of $31.90 million for the quarter, compared to the consensus estimate of $29.07 million. FibroGen had a negative net margin of 102.86% and a negative return on equity of 27.70%. The company’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.48) EPS. analysts forecast that FibroGen Inc will post -1.58 earnings per share for the current year.
Several research firms recently commented on FGEN. ValuEngine upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday. BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 15th. Zacks Investment Research upgraded shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, June 8th. Finally, Mizuho reiterated a “buy” rating and set a $74.00 target price on shares of FibroGen in a research report on Tuesday. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $68.83.
Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of Montreal Can lifted its position in shares of FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 3,041 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of FibroGen by 41.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 1,147 shares during the period. Aperio Group LLC acquired a new position in shares of FibroGen in the 1st quarter worth approximately $207,000. Paloma Partners Management Co acquired a new position in shares of FibroGen in the 4th quarter worth approximately $255,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of FibroGen in the 1st quarter worth approximately $258,000. Hedge funds and other institutional investors own 63.07% of the company’s stock.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.